• Vaccine Name: NYVAC-JEV- prM/E/ NS1
• Target Pathogen: Japanese encephalitis virus
• Target Disease: Japanese encephalitis
• Vaccine Ontology ID: VO_0004780
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• PrM gene engineering:
  • Type: Recombinant vector construction
  • Description: A highly attenuated strain of vaccinia virus (NYVAC) was engineered to express the Japanese encephalitis virus (JEV) prM, E, and NS1 genes or the prM and E genes (Konishi et al., 1992).
  • Detailed Gene Information: Click Here.
• NS1 gene engineering:
  • Type: Recombinant vector construction
  • Description: A highly attenuated strain of vaccinia virus (NYVAC) was engineered to express the Japanese encephalitis virus (JEV) prM, E, and NS1 genes or the prM and E genes (Konishi et al., 1992).
  • Detailed Gene Information: Click Here.
• E gene engineering:
  • Type: Recombinant protein preparation
  • Description: A highly attenuated strain of vaccinia virus (NYVAC) was engineered to express the Japanese encephalitis virus (JEV) prM, E, and NS1 genes or the prM and E genes (Konishi et al., 1992).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001093
  • Description: (Konishi et al., 1992)
• Preparation: Highly attenuated strain of vaccinia virus (NYVAC) was engineered to express the Japanese encephalitis virus (JEV) prM, E, and NS1 genes or the prM and E genes (Konishi et al., 1992).
• Immunization Route: Intramuscular injection (i.m.)

Pig Response

• Vaccination Protocol: The recombinant viruses were tested as vaccine candidates in pigs, a natural host of JEV. JEV-neutralizing and hemagglutination-inhibiting antibodies appeared in swine sera 7 days after immunization with 108 PFU of the recombinant viruses and increased after a second dose at 28 days (Konishi et al., 1992).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: JEV challenge (d56) of the swine with 2 × 10^8 PFU of JEV (Konishi et al., 1992).
• Efficacy: The JEV levels detected in the serum after JEV challenge were significantly reduced in animals inoculated with the recombinant viruses (Konishi et al., 1992).